2018
Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial
Sharma A, Ambrosy AP, DeVore AD, Margulies KB, McNulty SE, Mentz RJ, Hernandez AF, Felker G, Cooper LB, Lala A, Vader J, Groake JD, Borlaug BA, Velazquez EJ. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. ESC Heart Failure 2018, 5: 1035-1043. PMID: 30120812, PMCID: PMC6300815, DOI: 10.1002/ehf2.12334.Peer-Reviewed Original ResearchConceptsWeight loss agentsHeart failureEjection fractionHF hospitalizationNew York Heart Association functional class IIIGlucagon-like peptide-1 (GLP-1) receptor antagonistHeart Failure Treatment studyWeight lossAcute HF hospitalizationEfficacy of liraglutideRecent HF hospitalizationFunctional class IIILast study visitReduced ejection fractionAdvanced heart failureCardiovascular outcome trialsMedian ejection fractionAnalysis of patientsLiraglutide useMultivariable adjustmentStudy drugObese patientsOutcome trialsMedian agePrimary outcome
2012
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial
Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. The Lancet 2012, 381: 537-545. PMID: 23219284, DOI: 10.1016/s0140-6736(12)61343-9.Peer-Reviewed Original ResearchConceptsCardiovascular event ratesBody mass indexNormal weightPrimary endpointObese patientsEvent ratesCardiovascular outcomesCardiovascular protectionHypertension treatmentObese individualsHigher cardiovascular event ratesHigh-risk hypertensive patientsNon-fatal myocardial infarctionAmlodipine-based therapyAvoiding Cardiovascular EventsPatient’s cardiovascular outcomeSuperior cardiovascular protectionSystolic Hypertension (ACCOMPLISH) trialPrimary event rateSingle-pill combinationPrevious clinical trialsNormal weight categoryCardiovascular deathCardiovascular eventsHypertension trials
2011
Hypertension and Obesity as Cardiovascular Risk Factors among HIV Seropositive Patients in Western Kenya
Bloomfield GS, Hogan JW, Keter A, Sang E, Carter EJ, Velazquez EJ, Kimaiyo S. Hypertension and Obesity as Cardiovascular Risk Factors among HIV Seropositive Patients in Western Kenya. PLOS ONE 2011, 6: e22288. PMID: 21779407, PMCID: PMC3136516, DOI: 10.1371/journal.pone.0022288.Peer-Reviewed Original ResearchConceptsPrevalence of hypertensionOverweight/obesityLarge HIV treatment programCardiovascular risk factorsHIV treatment programsLogistic regression analysisRisk factorsSystolic/diastolic blood pressureAssociated cardiovascular risk factorsTreatment programMultiple logistic regression analysisHIV-seropositive individualsHIV-seropositive patientsDiastolic blood pressureOverweight/obesePrevalence of HIVPercent of menAge categoriesOrdinal logistic regression analysisRegression analysisHigher age categoriesElectronic medical recordsWestern KenyaCD4 countSeropositive patients